Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulbactam Sodium

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
20
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulbactam Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CG01

Repurposing investigation

Sulbactam Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 5 lab records
  • E. coli: measured active in 10 of 13 lab records
  • K. pneumoniae: measured active in 0 of 2 lab records
Open Sulbactam Sodium in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulbactam Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Zithromax EV in Community-Acquired Pneumonia (CAP)

    NCT00137007 · start 2003-11

    Registered record
    Registry ID
    NCT00137007
    Conditions
    Pneumonia
    Interventions
    Azithromycin; Ampicillin/sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-09
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionAzithromycin; Ampicillin/sulbactam
    PhasePhase 4
    Registry statusCompleted

  • Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease

    NCT01662765 · start 2003-11

    Registered record
    Registry ID
    NCT01662765
    Conditions
    Pilonidal Sinus; Sinus; Dermal, Pilonidal; Umbilical Granuloma
    Interventions
    Surgery; conservative
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-11
    Completion
    2012-05
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPilonidal Sinus; Sinus; Dermal, Pilonidal; Umbilical Granuloma
    InterventionSurgery; conservative
    PhaseNot applicable
    Registry statusCompleted

  • The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.

    NCT00356148 · start 2003-10

    Registered record
    Registry ID
    NCT00356148
    Conditions
    Breast Cancer
    Interventions
    Ampicillin/Sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2010-05
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAmpicillin/Sulbactam
    PhasePhase 4
    Registry statusCompleted

  • BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

    NCT01045902 · start 2001-02

    Registered record
    Registry ID
    NCT01045902
    Conditions
    Pneumonia, Aspiration; Lung Abscess
    Interventions
    Avelox (Moxifloxacin, BAY12-8039); Sulbactam/Ampicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2005-01
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Aspiration; Lung Abscess
    InterventionAvelox (Moxifloxacin, BAY12-8039); Sulbactam/Ampicillin
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

    NCT00044746 · start 2000-10

    Registered record
    Registry ID
    NCT00044746
    Conditions
    Diabetes Mellitus; Diabetic Foot
    Interventions
    Piperacillin/Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-10
    Completion
    2003-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Diabetic Foot
    InterventionPiperacillin/Tazobactam
    PhasePhase 4
    Registry statusCompleted